Skip to main content

Healthy Male Participants

5
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

EA Pharma
EA PharmaJapan - Tokyo
2 programs
2
E3112Phase 11 trial
[14C]-E6007Phase 11 trial
Active Trials
NCT03922633Completed24Est. Oct 2020
NCT03444818Completed6Est. Jun 2018
Agios Pharmaceuticals
Agios PharmaceuticalsMA - Cambridge
1 program
1
AG-881Phase 11 trial
Active Trials
NCT03960502Completed5Est. Sep 2019
Biocon
BioconIndia - Bangalore
1 program
1
Bmab3000Phase 11 trial
Active Trials
NCT07299955Recruiting150Est. Jun 2026
Genentech
GenentechCA - Oceanside
1 program
1
NXT007Phase 11 trial
Active Trials
NCT06189508Completed48Est. Dec 2024
Eisai
EisaiChina - Liaoning
2 programs
E3112PHASE_1
[14C]-E6007PHASE_1
Bristol Myers Squibb
1 program
BMS-986322PHASE_11 trial
Active Trials
NCT06088264Completed8Est. Dec 2023
Roche
RocheSTAVANGER NORWAY, Norway
1 program
NXT007PHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioconBmab3000
GenentechNXT007
Bristol Myers SquibbBMS-986322
Agios PharmaceuticalsAG-881
EA PharmaE3112
EA Pharma[14C]-E6007

Clinical Trials (6)

Total enrollment: 241 patients across 6 trials

A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

Start: Feb 2026Est. completion: Jun 2026150 patients
Phase 1Recruiting

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

Start: Feb 2024Est. completion: Dec 202448 patients
Phase 1Completed

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Start: Oct 2023Est. completion: Dec 20238 patients
Phase 1Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Start: May 2019Est. completion: Sep 20195 patients
Phase 1Completed

A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Start: Apr 2019Est. completion: Oct 202024 patients
Phase 1Completed

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Start: Apr 2018Est. completion: Jun 20186 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 241 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.